DBVT · Why this verdict
Why DBV Technologies (DBVT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.0/10
ConfidenceHIGH
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
DBV Technologies is a pre-commercial biotech burning cash far above its minimal revenue, dependent on a single platform and in a confirmed downtrend, with an unreliable analyst target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline depends on the Viaskin technology platform, flagged as a HIGH concentration risk in the annual report. Bear case | The Viaskin platform advances without a setback during the next four quarters. | ↑Improving |
| CounterA single successful platform is how binary biotech value is created, and implied volatility of 99% already prices in this dependence. | ||
Free cash flow is -2082% of revenue and the Rule of 40 reads -2135, an extreme burn rate relative to sales. Quality breakdown | Cash burn narrows as pipeline spending winds down or revenue scales over 12 months. | ↑Improving |
| CounterFor a pre-commercial biotech, burn ratios are inflated by tiny revenue and may not signal funding stress. | ||
Quarterly revenue was only $0.7M for June 2026, down from $2.774M in September 2025, and the next-quarter estimate is $0.58M. Revenue quarters | Quarterly revenue recovers above prior levels within 12 months. | ↓Deteriorating |
| CounterThe revenue figures conflict with yfinance, which shows $0 for every quarter, so the true revenue base is uncertain. | ||
The stock is below its 200-day average with a slope of -5.5% per 30 days and sits 63% off its 52-week high. Momentum breakdown | The long-term average flattens and the price stabilizes within 12 months. | ↓Deteriorating |
| CounterRising on-balance volume suggests accumulation, which can precede a trend reversal. | ||
A raw analyst target of $38.61 against a $9.75 price (4.0x) was rejected as implausible, so the 296% analyst upside figure is not reliable. Bear case | A credible analyst target emerges that is consistent with the share price. | ↑Improving |
| CounterA 4x target could reflect real expected value if the late-stage program succeeds, so rejecting it may understate upside. | ||
The pipeline depends on the Viaskin technology platform, flagged as a HIGH concentration risk in the annual report.
↑ImprovingBear case
- Expectation
- The Viaskin platform advances without a setback during the next four quarters.
CounterA single successful platform is how binary biotech value is created, and implied volatility of 99% already prices in this dependence.
Free cash flow is -2082% of revenue and the Rule of 40 reads -2135, an extreme burn rate relative to sales.
↑ImprovingQuality breakdown
- Expectation
- Cash burn narrows as pipeline spending winds down or revenue scales over 12 months.
CounterFor a pre-commercial biotech, burn ratios are inflated by tiny revenue and may not signal funding stress.
Quarterly revenue was only $0.7M for June 2026, down from $2.774M in September 2025, and the next-quarter estimate is $0.58M.
↓DeterioratingRevenue quarters
- Expectation
- Quarterly revenue recovers above prior levels within 12 months.
CounterThe revenue figures conflict with yfinance, which shows $0 for every quarter, so the true revenue base is uncertain.
The stock is below its 200-day average with a slope of -5.5% per 30 days and sits 63% off its 52-week high.
↓DeterioratingMomentum breakdown
- Expectation
- The long-term average flattens and the price stabilizes within 12 months.
CounterRising on-balance volume suggests accumulation, which can precede a trend reversal.
A raw analyst target of $38.61 against a $9.75 price (4.0x) was rejected as implausible, so the 296% analyst upside figure is not reliable.
↑ImprovingBear case
- Expectation
- A credible analyst target emerges that is consistent with the share price.
CounterA 4x target could reflect real expected value if the late-stage program succeeds, so rejecting it may understate upside.
Per-dimension breakdown
Quality
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 9.8 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -3025% of revenue
- ▸Rule of 40: -3068 (fail)
Growth
0.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
- ▸Declining revenue: -43%
Momentum
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 9.0 |
| OBV | 1.0 |
| MA position | 4.0 |
| Volume | 2.5 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -7.2%/30d — confirmed downtrend
Sentiment
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.7 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (7.0) — signal dampened
- ▸Analyst upside: 277%
Insider
4.6/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.9 |
| notable moves | 3.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 2.1 |
Technical
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.3 |
| support resistance | 4.1 |
| 52w position | 0.0 |
Risk (lower is worse)
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.3 |
| days to cover | 8.4 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 4.2 |
| debt equity | 9.8 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:140d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.2<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+7.0%
Downside
13.4%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 59
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -62% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.3) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:4.2<4.5, DEATH_CROSS:HARD_BLOCK) reinforce the read. Current asymmetry R:R is 0.00 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.3, Risk (lower is worse) at 7.0, and Value at 5.0; the weakest are Growth at 0.0, Technical at 2.5, and Peer rank at 3.2. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Cash Burn
Trip ifFree cash flow margin rises above -1000% of revenue from the current -2082%.
- P2Minimal And Falling Revenue
Trip ifQuarterly revenue exceeds $3M, above the $2.774M September 2025 level.
- P3Confirmed Downtrend
Trip ifThe 200-day moving average slope rises above 0% per 30 days from the current -5.5%.
- P4Single Platform Pipeline Dependence
Trip ifThe pipeline includes more than 1 independent platform.
- P5Implausible Analyst Target
Trip ifShare price rises above $19 from the current $9.75, reaching half of the rejected $38.61 target.